CTLA4 and colorectal carcinoma: Despite toxicity, Nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) is a promising new treatment option for patients with MMRd/MSI-H CRC, with high response rates, encouraging progression-free survival and overall survival at 12 months (37).